We are live on ! Find out more
GBIO

Generation Bio

Delisted

GBIO was delisted on the 6th of February, 2026.

75 hedge funds and large institutions have $136M invested in Generation Bio in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 22 increasing their positions, 28 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.06% less ownership

Funds ownership: 8.34%8.28% (-0.06%)

3% less funds holding

Funds holding: 7775 (-2)

13% less capital invested

Capital invested by funds: $156M → $136M (-$20M)

21% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 28

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

Holders
75
Holders Change
-2
Holders Change %
-2.6%
% of All Funds
1.08%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
5
Increased
22
Reduced
28
Closed
7
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$23.1M -$429K -16,204 -2%
AVLSA
2
Atlas Venture Life Science Advisors
Massachusetts
$20.5M
Fidelity Investments
3
Fidelity Investments
Massachusetts
$13.1M +$41.4K +1,566 +0.3%
BG
4
Bellevue Group
Switzerland
$9.68M
BlackRock
5
BlackRock
New York
$8.44M +$322K +12,175 +4%
Bank of America
6
Bank of America
North Carolina
$7.37M +$4.34K +164 +0.1%
SL
7
Siren LLC
Connecticut
$7.37M +$7.89M +298,273 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$6.51M +$125K +4,715 +2%
EC
9
EcoR1 Capital
California
$5.06M
BBA
10
Baker Bros. Advisors
New York
$4.8M +$1.95M +73,799 +61%
Goldman Sachs
11
Goldman Sachs
New York
$2.93M -$230K -8,682 -7%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$2.81M +$8.62K +326 +0.3%
Morgan Stanley
13
Morgan Stanley
New York
$2.47M +$167K +6,327 +7%
State Street
14
State Street
Massachusetts
$2.45M +$30.9K +1,167 +1%
UBS Group
15
UBS Group
Switzerland
$2.09M +$23.9K +904 +1%
PHS
16
PFM Health Sciences
California
$1.95M
Acadian Asset Management
17
Acadian Asset Management
Massachusetts
$1.5M +$29.7K +1,124 +2%
Renaissance Technologies
18
Renaissance Technologies
New York
$1.47M -$111K -4,210 -7%
D.E. Shaw & Co
19
D.E. Shaw & Co
New York
$1.21M +$1.61K +61 +0.1%
Dimensional Fund Advisors
20
Dimensional Fund Advisors
Texas
$1.09M -$117K -4,428 -9%
Charles Schwab
21
Charles Schwab
California
$1.05M +$23K +869 +2%
Northern Trust
22
Northern Trust
Illinois
$968K +$68.5K +2,591 +7%
TD Asset Management
23
TD Asset Management
Ontario, Canada
$828K
BCM
24
Bridgeway Capital Management
Texas
$800K +$132K +5,000 +18%
Los Angeles Capital Management
25
Los Angeles Capital Management
California
$730K -$122K -4,613 -13%

GBIO Hedge Fund Activity: Q3 2024 in Review

75 of the 6,969 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q3 2024, worth a combined $136M — down 13% from $156M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of GBIO and 5 opened new positions — a net loss of 2 holders — while 28 trimmed existing stakes and 22 added.

The largest buyer was Baker Bros. Advisors, adding an estimated $1.95M. The largest seller was Artal Group, exiting entirely with an estimated $7.98M sold.

  • 75 institutional investors held Generation Bio (GBIO) as of Q3 2024, down from 77 in Q2 2024.
  • Funds reported $136M of Generation Bio stock for Q3 2024, down 13% quarter-over-quarter.
  • 5 funds opened new Generation Bio positions in Q3 2024 and 7 closed out, a net change of -2 holders.
  • The largest Generation Bio buyer in Q3 2024 was Baker Bros. Advisors, an estimated $1.95M added.
  • The largest Generation Bio seller in Q3 2024 was Artal Group, an estimated $7.98M sold.

Based on aggregated 13F filings for Q3 2024.